Roche Diabetes Care India Introduces its Latest Integrated Diabetes Management Solution

Roche Diabetes Care (RDC) India today unveiled its latest Integrated Diabetes Management Solution (IDMS) with the launch of the “mySugr” app and “Accu-Chek Instant” blood glucose monitoring system, which together, form the next generation blood glucose monitoring system. Together, the mySugr App and Accu-Chek Instant bring advanced connectivity and accuracy*1 to help people with diabetes (PwDs) effortlessly manage their blood sugar levels and spend more time in in range. With this launch, RDC India aims to offer a collaborative, integrated and personalized approach for optimal therapy to people with diabetes or those at risk of developing the disorder. .

The mySugr app has more than 1 million registered users and roughly 20,000 reviews in the Apple App Store and Google Play Store, with an average rating of 4.6 stars*2.

The app provides bluetooth connectivity with Accu-Chek Instant, enabling the automatic uploading of data. The app provides easy access to blood glucose monitoring data to caregivers and doctors, enabling dynamic therapy modification. Through this app, users will also have access to diabetes coaching at their fingertips.

Accu-Chek Instant exceeds current accuracy criteria and provides wireless connectivity. It offers accuracy of 10/10 in blood sugar monitoring that exceeds the current ISO 15197:2013/EN ISO 15197:2015 system accuracy requirements*3. The easy to understand colour coded Target Range Indicator (TRI) helps in quick assessment. Its wide dosing area allows the placement of a small drop of blood anywhere along the blood application area, making the process of applying blood much easier.

“At RDC India we are committed to help patients maintain a vigil on their blood glucose levels. Successful diabetes management relies on efficient communication between people with diabetes, and their healthcare professionals. Key to doing this is providing an integrated platform of innovative hardware and digital technology that enables self-monitoring of blood sugar (SMBG) adoption and better diabetes management. This integrated platform allows patients, caregivers, and healthcare professionals to view, share, and access blood glucose data anytime for timely advice, and optimised treatment decisions. With the launch of the “mySugr app” and “Accu-Chek Instant”, RDC India is introducing an integrated personalised diabetes management solution for self-monitoring for enhanced personalised healthcare to patients across India.” says Dr. Gaurav Laroia, General Manager, Roche Diabetes Care India .

“The global epidemic of diabetes has rapidly spread to every country in Asia. Currently, more than 230 million Asian individuals are living with diabetes, accounting for approximately 55% of the world’s diabetic population, and this number is expected to exceed 355 million by 2040. Two Asian countries, China and India, are home to the largest number of patients with diabetes in the world. A recent study*4 suggested diabetes was associated with substantially increased risk of death from a broad spectrum of diseases particularly diabetes itself, renal disease, coronary heart disease and stroke. The associations were more evident among women and younger patients than among men and elderly patients.

There is an urgent need for implementing the diabetes management programs that are tailored to Indian population and the subsequent strong implementation of these programs. RDC India has taken a step ahead by establishing the Center of Excellence where the healthcare professionals will be trained on the “Integrated Diabetes Management – IDM”. IDM model will improve the physician-patient-dialogue, patient and physician satisfaction, patient adherence and glycemic control. It will also enable patients to master the complexity of managing diabetes to improve “Time in Range”, elaborated Dr. Varsha Khatry, Head – Medical & Scientific Affairs, Roche Diabetes Care India.

“India has around 80 million people with diabetes and almost an equal number with pre-diabetes. We want to make India the diabetes care capital of the world and empower the Indian people to take control of their diabetes. To manage the blood glucose levels better its important to have precise and accurate blood glucose management tools which are enabled with the latest technology and ease of use. Digital diabetes needs latest applications which can not only be signalling alarms for high or low sugar attacks but also motivational tools for behavior change. Roche Diabetes Care India has now the latest smart “instant” meter and “my sugar” app as management-cum-empowerment tools to make Indians confident and get better control of their sugars. My mantra to prevent diabetes for Indians is eat less, walk more, monitor regularly, sleep well and smile”, Dr Shashank Joshi, Endocrinologist, President, Indian Academy of diabetes Chair (elect) IDF South east Asia

“Accu-Chek Instant” is a high end monitoring system providing advanced accuracy and Target Range Indicator (TRI) that provides patients visual reassurance of their blood glucose values. With the launch of the new “mySugr” app and “Accu-Chek Instant” patients across India will get dual benefit of advanced data sharing capabilities to help simplify diabetes management.

About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. Being a global leader in integrated diabetes management, more than 5,000 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target range and experience true relief from the daily therapy routines. Roche Diabetes Care collaborates with caregivers, healthcare providers and payers to optimally manage this complex condition and contribute to sustainable care structures. Under the brand Accu-Chek and in collaboration with partners, Roche Diabetes Care creates value by providing integrated solutions to monitor glucose levels, deliver insulin and track as well as contextualize relevant data points for a successful therapy. By establishing a leading open ecosystem, connecting devices, digital solutions, Roche Diabetes Care will enable optimal personalised diabetes management and thus improve therapy outcomes. Since 2017, mySugr app with its world-leading mobile diabetes management app and services is part of Roche Diabetes Care. For more information, please visit http://www.accu-chek.com and http://www.mysugr.com.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s